Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir

Darunavir (DRV) is a potent antiviral drug used for treatment of infections with human immunodeficiency virus (HIV). Effective and safe treatment with DRV requires its therapeutic drug monitoring (TDM) in patient’s plasma during therapy. To support TDM of DRV, a specific antibody with high affinity...

Full description

Bibliographic Details
Main Authors: Ibrahim A. Darwish, Abdulrahman A. Almehizia, Awwad A. Radwan, Rashed N. Herqash
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/25/18/4075
_version_ 1827706722872983552
author Ibrahim A. Darwish
Abdulrahman A. Almehizia
Awwad A. Radwan
Rashed N. Herqash
author_facet Ibrahim A. Darwish
Abdulrahman A. Almehizia
Awwad A. Radwan
Rashed N. Herqash
author_sort Ibrahim A. Darwish
collection DOAJ
description Darunavir (DRV) is a potent antiviral drug used for treatment of infections with human immunodeficiency virus (HIV). Effective and safe treatment with DRV requires its therapeutic drug monitoring (TDM) in patient’s plasma during therapy. To support TDM of DRV, a specific antibody with high affinity is required in order to develop a sensitive immunoassay for the accurate determination of DRV in plasma. In this study, two new and different immunogens were prepared and characterized. These immunogens were the DRV conjugates with keyhole limpet hemocyanin (KLH) protein. The first immunogen (DRV-KLH) was prepared by zero-length direct linking of DRV via its aromatic amino group with the tyrosine amino acid residues of KLH by diazotization/coupling reaction. The second immunogen (G-DRV-KLH) was prepared by conjugation of the N-glutaryl derivative of DRV (G-DRV) with KLH. The 5-carbon atoms-spacing G-DRV hapten was synthesized by reaction of DRV via its aromatic amino group with glutaric anhydride. The reaction was monitored by HPLC and the chemical structure of G-DRV was confirmed by mass, <sup>1</sup>H-NMR, and <sup>13</sup>C-NMR spectroscopic techniques. The hapten (G-DRV) was linked to the KLH protein by water-soluble 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) coupling procedure. The pertinence of the coupling reactions of haptens to protein was confirmed, and the immunogens were characterized by ultraviolet (UV) spectrophotometry. Both DRV-KLH and G-DRV-KLH were used for the immunization of animals and the animal’s antiserum that showed the highest affinity was selected. The collected antiserum (polyclonal antibody) had very high affinity to DRV (IC<sub>50</sub> value = 0.2 ng mL<sup>−1</sup>; defining IC<sub>50</sub> as the DRV concentration that can inhibit antibody binding by 50% of its maximum binding) and high specificity to DRV among other drugs used in the combination therapy with DRV. Cumulative results from direct and competitive enzyme-linked immunosorbent assay (ELISA) using this polyclonal antibody proved that the immunogens were highly antigenic and elicited a specific polyclonal antibody. The produced polyclonal antibody is valuable for the development of highly sensitive and selective immunoassays for TDM of DRV.
first_indexed 2024-03-10T16:31:35Z
format Article
id doaj.art-318c460834774f36a277f339815568b5
institution Directory Open Access Journal
issn 1420-3049
language English
last_indexed 2024-03-10T16:31:35Z
publishDate 2020-09-01
publisher MDPI AG
record_format Article
series Molecules
spelling doaj.art-318c460834774f36a277f339815568b52023-11-20T12:47:02ZengMDPI AGMolecules1420-30492020-09-012518407510.3390/molecules25184075Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for DarunavirIbrahim A. Darwish0Abdulrahman A. Almehizia1Awwad A. Radwan2Rashed N. Herqash3Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaKayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2460, Riyadh 11451, Saudi ArabiaMedicinal Aromatic and Poisonous Plant Research Centre, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDarunavir (DRV) is a potent antiviral drug used for treatment of infections with human immunodeficiency virus (HIV). Effective and safe treatment with DRV requires its therapeutic drug monitoring (TDM) in patient’s plasma during therapy. To support TDM of DRV, a specific antibody with high affinity is required in order to develop a sensitive immunoassay for the accurate determination of DRV in plasma. In this study, two new and different immunogens were prepared and characterized. These immunogens were the DRV conjugates with keyhole limpet hemocyanin (KLH) protein. The first immunogen (DRV-KLH) was prepared by zero-length direct linking of DRV via its aromatic amino group with the tyrosine amino acid residues of KLH by diazotization/coupling reaction. The second immunogen (G-DRV-KLH) was prepared by conjugation of the N-glutaryl derivative of DRV (G-DRV) with KLH. The 5-carbon atoms-spacing G-DRV hapten was synthesized by reaction of DRV via its aromatic amino group with glutaric anhydride. The reaction was monitored by HPLC and the chemical structure of G-DRV was confirmed by mass, <sup>1</sup>H-NMR, and <sup>13</sup>C-NMR spectroscopic techniques. The hapten (G-DRV) was linked to the KLH protein by water-soluble 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) coupling procedure. The pertinence of the coupling reactions of haptens to protein was confirmed, and the immunogens were characterized by ultraviolet (UV) spectrophotometry. Both DRV-KLH and G-DRV-KLH were used for the immunization of animals and the animal’s antiserum that showed the highest affinity was selected. The collected antiserum (polyclonal antibody) had very high affinity to DRV (IC<sub>50</sub> value = 0.2 ng mL<sup>−1</sup>; defining IC<sub>50</sub> as the DRV concentration that can inhibit antibody binding by 50% of its maximum binding) and high specificity to DRV among other drugs used in the combination therapy with DRV. Cumulative results from direct and competitive enzyme-linked immunosorbent assay (ELISA) using this polyclonal antibody proved that the immunogens were highly antigenic and elicited a specific polyclonal antibody. The produced polyclonal antibody is valuable for the development of highly sensitive and selective immunoassays for TDM of DRV.https://www.mdpi.com/1420-3049/25/18/4075darunavirhuman immunodeficiency viruspolyclonal antibodyimmunoassaytherapeutic drug monitoring
spellingShingle Ibrahim A. Darwish
Abdulrahman A. Almehizia
Awwad A. Radwan
Rashed N. Herqash
Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir
Molecules
darunavir
human immunodeficiency virus
polyclonal antibody
immunoassay
therapeutic drug monitoring
title Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir
title_full Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir
title_fullStr Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir
title_full_unstemmed Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir
title_short Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir
title_sort preparation and characterization of two immunogens and production of polyclonal antibody with high affinity and specificity for darunavir
topic darunavir
human immunodeficiency virus
polyclonal antibody
immunoassay
therapeutic drug monitoring
url https://www.mdpi.com/1420-3049/25/18/4075
work_keys_str_mv AT ibrahimadarwish preparationandcharacterizationoftwoimmunogensandproductionofpolyclonalantibodywithhighaffinityandspecificityfordarunavir
AT abdulrahmanaalmehizia preparationandcharacterizationoftwoimmunogensandproductionofpolyclonalantibodywithhighaffinityandspecificityfordarunavir
AT awwadaradwan preparationandcharacterizationoftwoimmunogensandproductionofpolyclonalantibodywithhighaffinityandspecificityfordarunavir
AT rashednherqash preparationandcharacterizationoftwoimmunogensandproductionofpolyclonalantibodywithhighaffinityandspecificityfordarunavir